How chronic inflammation tips the balance of immune cells to promote liver cancer

Study explains success of some types of cancer immunotherapy, provides new targets for the development of additional immunotherapies Chronic inflammation is known to drive many cancers, especially liver cancer. Researchers have long thought that's because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chron

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Liver cancer symptoms: These are the eight signs of the DEADLY condition

LIVER cancer rates are rising, with thousands killed every year. But what are the symptoms? Liver cancer is a serious form of the disease that kills over 5,000 people a year. According to Cancer Research UK, rates have risen by 142 per cent since the 1990s. Primary liver cancer - that begins in the liver - is less common then secondary liver cancer, which begins elsewhere in the body and spreads to the liver. According to the NHS, the exact cause

Alcohol Induced Cirrhosis Found Less Likely to Cause Liver Cancer Than Previously Thought Compared to Virally Induced Cirrhosis

Although those with alcohol-induced cirrhosis do not exhibit nearly as high a risk of HCC as those with HCV, further findings indicated that 1.1% of patients with cryptogenic, 3.2% with autoimmune or metabolic disease, and 4% with chronic viral hepatitis developed HCC within 10 years. In a population-based cohort study published in Alimentary Pharmacology and Therapeutics, researchers from the United Kingdom investigated the overall risk of developing hep